2019

Our medical news may contain material that is considered promotional and is therefore intended for medical journalists and health care professionals only. By clicking through to see medical news, you are confirming that you are a medical journalist or healthcare professional.

Q2

Press releases
Shionogi and Ferrer conclude a contract for the promotion in Spain of▼ Rizmoic® (naldemedine), a therapeutic agent for opioid-induced constipation
Press releases
Shionogi and Molteni conclude a contract for the commercialisation of Rizmoic® (naldemedine) an Opioid Induced Constipation (OIC) therapeutic agent in Italy and Poland
Press releases
Shionogi Concludes a Contract for the Commercialization of Rizmoic® (naldemedine), an Opioid-Induced Constipation Therapeutic Agent, in Germany, the UK, and the Netherlands
Medical News
Shionogi to Present New Data at European Congress of Clinical Microbiology and Infectious Diseases 2019.pdf
Medical News
Shionogi announces submission of cefiderocol Marketing Authorisation Application
Medical News
Shionogi to present clinical data on lusutrombopag at the International Liver Congress™ 2019 of the European Association for the Study of the LIiver (EASL)

Q1

Medical News
Shionogi announces European Union Marketing Authorisation for lusutrombopag
Medical News
Shionogi announces European Union Marketing Authorisation for Rizmoic® (naldemedine)

Back  number